In the multicenter DESTINY-Lung02 trial, T-DXd was evaluated at two doses, 5.4 mg/kg and 6.4 mg/kg, in 152 patients with HER2-mutated metastatic NSCLC [33]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.